In vitro study demonstrates that miR-155 directly suppresses MARCH7 to enhance cell viability and invasion in breast cancer models, suggesting a key oncogenic pathway.
miR-155 is an oncogenic microRNA implicated in breast cancer, but its downstream post-transcriptional targets remain incompletely defined. This study tested membrane-associated RING-CH 7 (MARCH7) as a direct miR-155 target and examined associated molecular and cellular phenotypes in MCF-7 and MDA-MB-231 breast cancer cells. Basal miR-155 expression was assessed in MCF-10A, MCF-7, and MDA-MB-231 cells. MCF-7 cells were analyzed by MTT, RT-qPCR, Western blotting, bioinformatic prediction, dual-luciferase reporter assays, and MARCH7 knockdown; MDA-MB-231 cells were additionally evaluated by MTT, RT-qPCR, wound-healing, and Transwell invasion assays. miR-155 was more abundant in the breast cancer cell lines than in MCF-10A cells. In MCF-7 cells, miR-155 overexpression increased MTT-derived metabolic viability, reduced MARCH7 and PTEN expression, increased Cyclin D1, reduced cleaved caspase-3, and was associated with increased PI3K and AKT phosphorylation. In MDA-MB-231 cells, RT-qPCR confirmed successful miR-155 modulation, whereas MTT changes were modest; these small changes may reflect either model/endpoint differences or limited sensitivity of the MTT assay under the tested conditions. Dual-luciferase assays confirmed direct targeting of the MARCH7 3′-UTR by miR-155, while miR-155 inhibition markedly reduced MDA-MB-231 migration and invasion. These findings establish MARCH7 as a direct miR-155 target in the models examined. The PTEN/PI3K/AKT changes are associated downstream findings and are not yet proven to be mediated specifically by MARCH7.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: